Diabetes will be the 800-pound gorilla in healthcare for the foreseeable future, according to a crystal ball-gazing white paper from Euro RSCG which pegs the rise of telemedicine, a wave of "cyberchondria" and soaring rates of medical tourism as among the emerging trends reshaping the practice of medicine.
Years after generic competition begins eroding Lipitor revenues (and RA biologic Humira overtakes it as the world's biggest selling drug), Pfizer will still be the industry's sales leader, but Sanofi and Novartis will run closely behind, according to EvaluatePharma's World Preview 2016.
Global pharma market growth will pick up steam in 2011, with growth of 5%-7% to $880 billion, over 4%-5% growth in 2010, according to IMS Health.
A report predicting that Humira will become the world's biggest product in two years' time generated positive news for the Abbott Labs arthritis drug. Several factors are driving the bullish forecast.
Global sales of pharmaceuticals will grow at a rate of 5%-8% annually over the next five years, IMS Health forecasts -- even as products with sales of more than $142 billion lose patent protection in top markets, reducing drug spending by $80-$100 billion.
The global market for pharmaceuticals is expected to grow by 4%-6% in 2010 - exceeding $825 billion - due in part to near-term growth in the US, according to an IMS Health forecast.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.